Yeast Synthetic Biology Platform Generates Novel Chemical Structures as Scaffolds for Drug Discovery

ABSTRACT: Synthetic biology has been heralded as a new bioengineering platform for the production of bulk and specialty chemicals, drugs, and fuels. Here, we report for the first time a series of 74 novel compounds produced using a combinatorial genetics approach in baker’s yeast. Based on the concept of “coevolution ” with target proteins in an intracellular primary survival assay, the identified, mostly scaffold-sized (200−350 MW) compounds, which displayed excellent biological activity, can be considered as prevalidated hits. Of the molecules found,>75 % have not been described previously; 20 % of the compounds exhibit novel scaffolds. Their structural and physicochemical properties comply with established rules of drug- and fragment-likeness and exhibit increased structural complexities compared to synthetically produced fragments. In summary, the synthetic biology approach described here represents a completely new, complementary strategy for hit and early lead identification that can be easily integrated into the existing drug discovery process